department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Dizal Pharmaceutical Co Ltd · pharmadog

PUBLIC COMPANY

Dizal Pharmaceutical Co Ltd

updated 1mo ago

community read0 votes

pipeline

3

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(3)

pipeline depth3 products

2Phase 21Marketed

Non-Small Cell Lung Cancer

Refractory Chronic Lymphocytic Leukemia (CLL)

Peripheral T-Cell Lymphomas (PTCL)

Tyrosine-protein kinase JAK1

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Dizal Pharmaceutical Co Ltd jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

Oncology3 NSCLC1

mentioned in

0news items

entity-linker matched

Active trials

phase1DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomacompletedn=17
phase3A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)recruitingn=218
phase2Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)recruitingn=165
phase2DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)recruitingn=150
phase1A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)not yet recruitingn=6
phase2DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)active not recruitingn=59
phase1A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)recruitingn=140
phase3A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)active not recruitingn=324

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?